Neuroinflammation and inner immune dysfunction are increasingly accepted as important
components of the etiopathogenesis of Parkinson's disease (PD). According to emerging …

Background Although evidence suggests that the prevalence of Parkinson's disease (PD) is
lower in smokers than in non-smokers, the mechanisms of nicotine-induced neuroprotection …

The inverse association between nicotine intake and Parkinson's disease (PD) is well
established and suggests that this molecule could be neuroprotective through anti …

Background: Parkinson's disease (PD) is associated with neurodegeneration of
dopaminergic neurons and an accompanying neuroinflammatory process in the substantia …

Background The α7 nicotinic acetylcholine receptor (α7 nAChR) negatively regulates the
synthesis and release of pro-inflammatory cytokines by immune cells. Our previous studies …

Neuroinflammation is crucial in the progression of neurodegenerative diseases. Thus,
controlling neuroinflammation has been proposed as an important therapeutic strategy for …

Parkinson's disease (PD) is the second most common neurodegenerative disorder and a
leading cause of disability. The current gold standard for PD treatment, L-Dopa, has limited …

Astrocytes have been implicated in the immune responses associated with Parkinson's
disease (PD). Inhibition of astrocyte apoptosis is a novel strategy for the treatment of PD …

Aging is an important risk factor for neurodegenerative diseases. The activation of α7
nicotinic acetylcholine receptor (α7nAChR) is involved in inflammation and cognition, but the …

Background α7 nicotinic acetylcholine receptors (nAChRs) are widely distributed throughout
the central nervous system and are reported to have neuroprotective properties. α7 nAChRs …